Olmezest Beta 40mg/50mg Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil 40mg and Metoprolol Succinate 50mg. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and decreased myocardial oxygen demand. This combination is indicated for the treatment of hypertension in patients who require dual therapy to achieve adequate blood pressure control. By targeting different mechanisms involved in blood pressure regulation, Olmezest Beta provides enhanced antihypertensive efficacy. It is also beneficial in reducing the risk of cardiovascular events in patients with hypertension and concomitant cardiac conditions such as ischemic heart disease or heart failure. Dosage should be individualized based on patient response and tolerability. Common adverse effects may include dizziness, fatigue, headache, and gastrointestinal disturbances. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.